ACQUISITION OF ACTIENT (Details) (USD $)				0 Months Ended	3 Months Ended		6 Months Ended		0 Months Ended				6 Months Ended			0 Months Ended
	Jun. 30, 2013	Dec. 31, 2012	Jun. 30, 2012	Apr. 26, 2013 Actient	Jun. 30, 2013 Actient	Jun. 30, 2012 Actient	Jun. 30, 2013 Actient	Jun. 30, 2012 Actient	Apr. 26, 2013 Actient Minimum	Apr. 26, 2013 Actient Maximum	Apr. 26, 2013 Actient Warrant	Apr. 26, 2013 Actient Urology item	Jun. 30, 2013 Actient Urology Sales milestone equal to $150 million	Jun. 30, 2013 Actient Urology Sales milestone exceeding $150 million	Jun. 30, 2013 Actient Urology Sales milestone exceeding $300 million	Apr. 26, 2013 Actient Respiratory item	Apr. 26, 2013 Actient TESTOPEL	Apr. 26, 2013 Actient Edex	Apr. 26, 2013 Actient Timm Medical	Apr. 26, 2013 Actient Striant	Apr. 26, 2013 Actient Theo-24	Apr. 26, 2013 Actient Semprex-D	Apr. 26, 2013 Actient Other products
ACQUISITION OF ACTIENT
Number of marketed products												4				2
Warrants issued (in shares)				1,250,000	1,250,000
Strike price of warrants (in dollars per share)	$ 27.36			$ 17.80
Term of warrants				10 years
Expected term											10 years
Expected volatility (as a percent)											50.00%
Risk-free interest rate (as a percent)											1.70%
Dividend yield (as a percent)											0.00%
Term loan				$ 225,000,000
Fair value of the total consideration
Base cash consideration	588,917,000		0	585,000,000
Cash and working capital adjustment				15,431,000
Contingent consideration				40,958,000
Warrants	12,000,000		0	12,000,000
Total consideration				653,389,000
Consideration representing compensation	(8,309,000)		0	(8,309,000)
Consideration allocated to net assets acquired				645,080,000
Achievement of cumulative net sales thresholds													15,000,000	10,000,000	25,000,000
Cumulative net sales													150,000,000	150,000,000	300,000,000
Maximum period for adjustments to purchase price allocation							1 year
Estimated fair values of the net assets acquired
Cash				11,514,000
Accounts receivable, trade				25,631,000
Inventory				21,704,000
Prepaid expenses and other current assets				4,061,000
Property and equipment				3,028,000
Purchased intangibles				667,000,000													60,848,000	7,052,000
Goodwill				113,369,000
Other long-term assets				6,116,000
Total assets acquired				852,423,000
Contingent consideration assumed				(72,900,000)
Other liabilities assumed				(29,906,000)
Deferred tax liabilities				(104,537,000)
Consideration allocated to net assets acquired				645,080,000
Fair value assigned to the product rights
Fair value				667,000,000													491,000,000	70,000,000	23,000,000	8,000,000	39,000,000	32,000,000	4,000,000
Estimated life in years																	12 years	11 years	10 years	10 years	9 years	10 years	2 years
Purchased intangibles				667,000,000													60,848,000	7,052,000
Royalties as percentage of net sales									6.00%	15.00%							12.00%
Royalties as percentage of net sales on crossing annual net sales of $20,000																		15.00%
Minimum annual net sales, above which royalty will be paid																		20,000,000
Royalty obligation that will cease				3,000,000
Goodwill	113,369,000	0		113,369,000
Intangibles and Goodwill are expected to be deductible for tax purposes				400,000,000
Pro forma results of operations
Net revenues					115,113,000	108,620,000	215,830,000	212,129,000
Net income (loss) attributable to the Company					$ (33,964,000)	$ (23,349,000)	$ (36,612,000)	$ 19,388,000
Net income (loss) per common share-
Basic (in dollars per share)					$ (0.69)	$ (0.48)	$ (0.74)	$ 0.40
Diluted (in dollars per share)					$ (0.69)	$ (0.47)	$ (0.74)	$ 0.39